CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply
Lancet Oncol
.
2022 Jan;23(1):e14-e15.
doi: 10.1016/S1470-2045(21)00722-1.
Authors
Dean A Fennell
1
,
Gareth Griffiths
2
,
Christian Ottensmeier
3
,
Gerard G Hanna
4
,
Sarah Danson
5
,
Peter Szlosarek
6
,
Mavis Nye
7
Affiliations
1
Leicester Cancer Research Centre, University of Leicester, Leicester, UK. Electronic address: df132@le.ac.uk.
2
Cancer Research UK Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
3
Clatterbridge Cancer Centre NHS Foundation trust, University of Liverpool, Liverpool, UK.
4
Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; Queen's University Belfast, Belfast, UK.
5
Weston Park Cancer Centre, University of Sheffield, Sheffield, UK.
6
Cancer Research UK Barts Centre, Queen Mary University of London, London, UK.
7
Mavis Nye Foundation, London, UK.
PMID:
34973224
DOI:
10.1016/S1470-2045(21)00722-1
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Humans
Immunotherapy / adverse effects
Mesothelioma* / drug therapy
Mesothelioma, Malignant*